Explore

Trendline Trendline
Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers
Trendline Trendline
Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for Clinical Advancement

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for Clinical Advancement

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for Clinical Advancement
Trendline Trendline
Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma

Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma

Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma
Trendline Trendline
Bora Group Acquires MacroGenics' Maryland Manufacturing Operations for $122.5 Million

Bora Group Acquires MacroGenics' Maryland Manufacturing Operations for $122.5 Million

Bora Group Acquires MacroGenics' Maryland Manufacturing Operations for $122.5 Million
Trendline Trendline
IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy with AI Enhancement

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy with AI Enhancement

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy with AI Enhancement
Trendline Trendline
Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026
Trendline Trendline
Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas

Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas

Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas
Trendline Trendline
FDA Approves Partner Therapeutics' Bizengri for Ultra-Rare Cancer Following Priority Voucher

FDA Approves Partner Therapeutics' Bizengri for Ultra-Rare Cancer Following Priority Voucher

FDA Approves Partner Therapeutics' Bizengri for Ultra-Rare Cancer Following Priority Voucher
Trendline Trendline
Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration
Trendline Trendline
Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaborations

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaborations

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaborations